TG Therapeutics Reports Strong 2025 BRIUMVI Revenue, Issues Bullish 2026 Guidance, and Outlines Key Pipeline Milestones
Summary
TG Therapeutics announced strong preliminary 2025 revenue and provided bullish 2026 guidance for its key drug BRIUMVI, alongside outlining significant development milestones for its pipeline.
Key Events
-
Strong 2025 Revenue Performance
Preliminary total global revenue for full year 2025 reached approximately $616 million, with U.S. BRIUMVI net product revenue at $594 million.
-
Bullish 2026 Revenue Guidance
The company projects total global revenue of $875-900 million for full year 2026, including $825-850 million from U.S. BRIUMVI sales, indicating substantial growth.
-
Key Development Milestones
Multiple pipeline catalysts are anticipated for 2026, including pivotal data for IV BRIUMVI dosing, preliminary Phase 1 azer-cel data in Progressive MS, and pivotal data for subcutaneous BRIUMVI.
-
Pipeline Expansion
Plans to initiate registration-directed and exploratory studies for BRIUMVI and azer-cel in new autoimmune indications beyond MS.
Analysis
TG Therapeutics has reported strong preliminary net product revenue for BRIUMVI in Q4 and full year 2025, exceeding $600 million globally. The company also provided robust 2026 revenue guidance, targeting $875-900 million in total global revenue, driven primarily by BRIUMVI U.S. sales. This significant growth trajectory, coupled with a detailed roadmap of anticipated development milestones for BRIUMVI (including subcutaneous formulation and new indications) and azer-cel, signals strong commercial momentum and a promising pipeline. Investors should view this as a positive indicator of the company's ability to execute on its commercial strategy and advance its therapeutic candidates.
At the time of this filing, TGTX was trading at $29.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.4B. The 52-week trading range was $25.28 to $46.48. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.